Allergy Therapeutics (LON:AGY) Hits New 12-Month Low – Should You Sell?

Allergy Therapeutics plc (LON:AGY)’s stock price reached a new 52-week low on Tuesday . The company traded as low as GBX 6 and last traded at GBX 6.38, with a volume of 398951 shares traded. The stock had previously closed at GBX 6.82.

Allergy Therapeutics Price Performance

The company has a debt-to-equity ratio of 629.58, a quick ratio of 1.48 and a current ratio of 1.13. The stock’s fifty day moving average price is GBX 8.72 and its 200-day moving average price is GBX 10.22. The firm has a market cap of £404.33 million, a PE ratio of -6.58, a P/E/G ratio of -30.70 and a beta of 0.87.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.